- In September 2024, the yellow fever vaccine market was projected to grow from $4.32 billion in 2023 to USD 5.56 billion by 2028, at a CAGR of 5.2%. This growth reflects increased global travel, heightened awareness of yellow fever prevention, and the implementation of international health regulations requiring vaccination for entry into certain regions
- In 2024, Asia Pacific held a 23% share of the global yellow fever vaccine market, with India contributing USD 124.99 million and projected to grow at a CAGR of 9.3% through 2031. This growth is driven by increasing preventive healthcare initiatives and government immunization programs.
- In October 2023, the Bill & Melinda Gates Foundation announced a USD 40 million investment to help African manufacturers develop mRNA vaccines, including for diseases like yellow fever. This initiative aims to address vaccine inequity and build vaccine self-reliance in Africa
- In 2023, the World Health Organization (WHO) recommended that travelers obtain a valid international certificate of vaccination or prophylaxis (ICVP) as proof of yellow fever vaccination required for entry into certain countries. This recommendation underscores the importance of vaccination for international travel and public health safety
- In 2023, North America accounted for the largest share of the travel vaccines market, with yellow fever vaccines being a significant component. The region's high awareness of travel-related health risks and government initiatives to promote vaccinations contribute to this market dominance.
